| Pinnacle Health & Rehab At Sanford | |
| 1142 Main St, Sanford, Maine 04073 | |
| (207) 324-2273 | |
| Name | Pinnacle Health & Rehab At Sanford |
|---|---|
| Location | 1142 Main St, Sanford, Maine |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 86 |
| Occupancy Rate | 70.58% |
| Medicare ID (CCN) | 205082 |
| Legal Business Name | Pinnacle Group Of Hudson Valley Ii Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1578567988 |
| Organization Name | GREENWOOD NURSING CARE CENTER, INC |
| Doing Business As | GREENWOOD CENTER |
| Address | 1142 Main St, Sanford, ME 04073 |
| Phone Number | 207-324-2273 |
News Archive
Regeneron and Sanofi today announced that the European Medicines Agency has accepted for review the Marketing Authorization Application for Praluent (alirocumab). Alirocumab is an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9) that is intended for the treatment of patients with hypercholesterolemia.
The best strategy for minimizing future influenza morbidity and mortality would be to concentrate vaccinations in school children and high-risk groups, according to a new research commentary by scientists at Emory University.
Producing effective epidermal electronics requires a strong, biocompatible interface between a biological surface and a sensor. Here, a KAIST team employed a calcium-modified silk fibroin as a biocompatible and strong adhesive.
Liver cancer is the fourth most common cause of cancer death worldwide and is growing rapidly due to the "diabesity pandemic."
The Groupe Européen de Curiethérapie European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) today announced results from a prospective, randomized, multicenter phase III study comparing accelerated partial breast irradiation (APBI) with interstitial multicatheter brachytherapy to whole breast irradiation (WBI).
› Verified 3 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Regeneron and Sanofi today announced that the European Medicines Agency has accepted for review the Marketing Authorization Application for Praluent (alirocumab). Alirocumab is an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9) that is intended for the treatment of patients with hypercholesterolemia.
The best strategy for minimizing future influenza morbidity and mortality would be to concentrate vaccinations in school children and high-risk groups, according to a new research commentary by scientists at Emory University.
Producing effective epidermal electronics requires a strong, biocompatible interface between a biological surface and a sensor. Here, a KAIST team employed a calcium-modified silk fibroin as a biocompatible and strong adhesive.
Liver cancer is the fourth most common cause of cancer death worldwide and is growing rapidly due to the "diabesity pandemic."
The Groupe Européen de Curiethérapie European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) today announced results from a prospective, randomized, multicenter phase III study comparing accelerated partial breast irradiation (APBI) with interstitial multicatheter brachytherapy to whole breast irradiation (WBI).
› Verified 3 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 11.82 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 2.99 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 76.6 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 2.63 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 2.71 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 17.46 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 3.05 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 99.62 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 10.85 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 89.06 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 22.02 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 16.59 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 5.61 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 100 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 53.34 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 94.74 | 82.93 |
News Archive
Regeneron and Sanofi today announced that the European Medicines Agency has accepted for review the Marketing Authorization Application for Praluent (alirocumab). Alirocumab is an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9) that is intended for the treatment of patients with hypercholesterolemia.
The best strategy for minimizing future influenza morbidity and mortality would be to concentrate vaccinations in school children and high-risk groups, according to a new research commentary by scientists at Emory University.
Producing effective epidermal electronics requires a strong, biocompatible interface between a biological surface and a sensor. Here, a KAIST team employed a calcium-modified silk fibroin as a biocompatible and strong adhesive.
Liver cancer is the fourth most common cause of cancer death worldwide and is growing rapidly due to the "diabesity pandemic."
The Groupe Européen de Curiethérapie European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) today announced results from a prospective, randomized, multicenter phase III study comparing accelerated partial breast irradiation (APBI) with interstitial multicatheter brachytherapy to whole breast irradiation (WBI).
› Verified 3 days ago